In a report issued on March 1, Liisa Bayko from JMP Securities reiterated a Buy rating on BioCryst (BCRX), with a price target of $16. The company’s shares closed yesterday at $8.35.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 17.0% and a 50.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Enanta Pharmaceuticals, and Sarepta Therapeutics.
Currently, the analyst consensus on BioCryst is a Moderate Buy with an average price target of $14, a 67.7% upside from current levels. In a report issued on February 26, H.C. Wainwright also maintained a Buy rating on the stock with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.95 and a one-year low of $4.53. Currently, BioCryst has an average volume of 750K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2018, Alane Barnes, the SVP, Chief Legal Officer of BCRX sold 44,290 shares for a total of $401,710.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.
